2013-08-23 09:14:19 - Fast Market Research recommends "Romania Pharmaceuticals & Healthcare Report Q3 2013" from Business Monitor International, now available
We forecast continued growth in Romania's pharmaceutical market due to greater private contributions to the cost of healthcare and a return to slight economic growth in 2013. The partial removal of elements of the clawback tax will undoubtedly provide the industry with a slight boost this year. In terms of debts and timeliness of payments, the CNAS is still within its remit to reimburse drugmakers some 210 days after request and almost RON6.3bn (EUR1.44bn) of debts remain unpaid to the industry. The tax remains most punitive for generic drugmakers with lower-value medicines and could lead to these cheaper medicines exiting the market. The tax continues to weigh down BMI's assessment of Romania's Pharmaceutical and Healthcare Risk/Reward ratings.
Headline Expenditure Projections
Pharmaceuticals: RON13.55bn (US$3.91bn) in 2012 to RON14.6bn (US$4.50bn) in 2013; +8.0% in local currency terms and +15% in US dollar terms. US dollar forecast up from Q213 on account of strengthening leu.
* Healthcare: RON33.99bn (US$9.80bn) in 2012 to RON36.35bn (US$11.17bn) in 2013; +6.9% in local currency terms and +13.9% in US dollar terms. US dollar forecast revised upwards from Q213 due to strength in local currency.
Full Report Details at
- www.fastmr.com/prod/670589_romania_pharmaceuticals_healthcare_re ..
Romania has a RRR score of 56out of 100, making it the seventh most attractive pharmaceutical market in the Central and Eastern Europe region. Although Romania presents a long term growth story, punitive taxes, pricing controls and a lack of funding by the state for reimbursing patients will moderate the Romanian market's attractiveness to drugmakers.
Key Trends And Developments
* In February 2013 the Romanian Constitutional Court ruled that part of the clawback tax was unconstitutional. The calculation method for determining the amount the industry had to pay the Romanian government used the post-VAT price of medicines, thereby inflating the amount due back to the government. The court ruled that drugmakers had been unfairly double-taxed by the provision.
* An estimated EUR85mn (US$110mn) was expected to be collected by the Romanian health ministry through the claw-back tax in 2012, supplementing the EUR33mn (US$43mn) allocated to the ministry by the government. The tax revenue, planned to be transferred to the single health insurance fund, was to be spent on hospitals, with priority given to regional network and emergency hospitals. Newly launched drugs and medical supplies supervision programmes in Romania were also reportedly to be allocated EUR880,000 (US$1.14mn).
* Private health providers and insurers have collaborated to offer Romanian consumers private health insurance. While most Romanians are registered on state health insurance (CNAS), this offering will likely be taken up by middle class Romanians tired of the country's dysfunctional healthcare system.
* In October 2012, it was revealed that medicines and sanitary materials for emergency care units would be procured centrally in Romania from 2013, according to statements made by the interim health minister Raed Arafat. The government will issue tenders for all medicines and sanitary materials that are used in the 63 state-funded emergency care centres in the country. The tenders will help to control cost in emergency care, thereby reducing healthcare expenditure. The public health departments and health units have also been asked by Arafat to spend all available funds so that none remains at the end of the year.
* A new proposal related to patient co-payment rules in Romania stipulates that patients with a compulsory health insurance policy might pay less in patient co-payments, reported PMR in September 2012. The proposal suggests RON2-RON4 (US$0.57-1.15) patient co-payment tariffs for a consultation, subject to the professional qualifications of the doctor. The proposal also recommends RON10-30 (US$2.87-8.63) patient tariffs for one day in hospital and RON20-40 (US$5.75-11.51) for an extended hospital stay.
* Around 88.5% of Romanians prefer innovative drugs for the treatment of serious illnesses, Business Review reported in October 2012, citing a survey conducted by the IMAS Marketing & Sondaje Institute. Almost 80% of respondents feel that it is imperative to buy innovative drugs; however, only 19.5% were able to distinguish between generic drugs and original drugs. Of the total 1,036 Romanians surveyed, 45% stated that they wanted access to innovative drugs and 17% preferred generic drugs.
BMI Economic View
With recently released data showing the Romanian economy grew by 0.3% year-on-year (y-o-y) in Q412, we reiterate our view that the country's economy will improve modestly in 2013, forecasting real GDP growth of 1.7%. We expect improving private consumption and the recovering agricultural sector to support growth over the next few quarters, but caution that weak gross fixed capital formation and suppressed external demand will prevent a more significant uptick in economic growth in 2013 and 2014. BMI Political View
We expect political instability to continue posing significant problems for Romania over the next few quarters, despite the USL's landslide victory in last December's parliamentary election In particular, we expect persistent allegations of corruption, the strained Ponta-Basescu relationship, and ongoing austerity to weigh on the country's political outlook going forward.
About Business Monitor International
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at www.fastmr.com/catalog/publishers.aspx?pubid=1010
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.